Other Biopharmaceuticals

Astellas Pharma Inc.

Zydus Lifesciences Reaches Settlement Agreement with Astellas and Pays Settlement Fees

Lupin and Astellas Pharma Reach Settlement Postponing Generic Drug Launch

ALPMY

4503

Astellas Pharma Inc. will present new oncology data at the 2026 ASCO Annual Meeting, highlighting long-term outcomes and clinical applications across various cancer types. Key presentations include a 3.5-year follow-up on enfortumab vedotin for urothelial carcinoma and updates on prostate cancer treatments. Additionally, Astellas will introduce findings on fezolinetant for managing vasomotor symptoms in breast cancer patients. These presentations underscore Astellas' commitment to enhancing cancer care.

- Astellas Pharma will present 10 abstracts, including two oral presentations, at the 2026 ASCO Annual Meeting, highlighting its commitment to oncology research.  
- Key topics include the effectiveness of enfortumab vedotin combined with pembrolizumab for urothelial carcinoma and updates on fezolinetant for managing symptoms in breast cancer patients.  
- These presentations aim to enhance clinical understanding and improve treatment decision-making for various cancer types.

StockTitan

Astellas Pharma

Pfizer

Astellas to Present Data on Long-Term Outcomes and Clinical Use of Its Portfolio Across Disease Stages at ASCO 2026 | PFE Stock News

TBXU

The Scottish Medicines Consortium has recommended the reimbursement of enfortumab vedotin with pembrolizumab for adults with unresectable or metastatic urothelial cancer. This decision allows access to a treatment that significantly improves overall survival through the NHS. The EV-302 phase 3 trial showed a median overall survival of 33.8 months for the combination compared to 15.9 months for chemotherapy. Experts believe this combination will reshape first-line treatment for advanced bladder cancer patients in Scotland.

PharmaTimes

Direxion Daily Biotech Top 5 Bull 2X ETF

Invesco Biotechnology & Genome ETF

ALPS Medical Breakthrough

Direxion S&P Biotech Bull 3X

VanEck Biotech ETF

Proshares Ultra Nasdaq Biotech

Ark Genomic Revolution ETF

iShares Biotechnology ETF

SPDR S&P Biotech

First Trust NYSE Arca Biotech Index Fd

Invesco Nasdaq Biotechnology ETF

SMC backs first-line metastatic bladder cancer combination after trial results

Astellas Pharma Inc. (TSE:4503) reported yearly earnings, with shares dropping 7.8% to JP¥2,306. Revenues met forecasts at JP¥2.1t, but EPS fell short at JP¥163, missing estimates by 4.8%. Analysts forecast revenues of JP¥2.24t for 2027, reflecting a 4.5% growth, while EPS is expected to rise 13% to JP¥184. Despite a downgrade in EPS estimates, the consensus price target remains unchanged at JP¥2,418. Astellas Pharma's growth is projected to align with industry trends, but analysts express varied opinions on the stock's future.

Simplywall

Astellas Pharma Inc. (TSE:4503) Just Reported Yearly Earnings: Have Analysts Changed Their Mind On The Stock?

Astellas Pharma (TSE:4503) reported a FY 2026 scorecard with second half revenue of ¥1.1t and basic EPS of ¥80.33, reflecting a significant increase in net profit margins to 13.6% from 2.7% a year earlier. Despite bullish narratives citing strong earnings growth, analysts predict potential earnings contraction in the medium term. The stock trades at a trailing P/E of 14.1x, below industry averages, but concerns about revenue declines due to patent expiries and pricing pressures persist. Investors are advised to consider both optimistic and cautious perspectives on the company's future performance.

Astellas Pharma (TSE:4503) Margin Surge To 13.6% Tests Bearish Earnings Narratives

U.S. FDA Grants Priority Review to sBLA for PADCEV™ + Keytruda® as Perioperative Treatment for Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibility | PFE Stock News

iShares US Pharma

VG Health

U.S. FDA Grants Priority Review to sBLA for PADCEV™ + Keytruda® as Perioperative Treatment for Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibility | PFE Stock News

UBS analyst maintained a Hold rating on Astellas Pharma today and set a price target of Yen2,600.00.Claim 30% Off TipRanksUnlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks The word on The Street in general, suggests a Hold analyst consensus rating for Astellas Pharma with a Yen2,404.50 average price target.

Tip Ranks

UBS Group AG

Astellas Pharma (ALPMF) Receives a Hold from UBS

Astellas Pharma's Phase 3 trial of XOSPATA for acute myeloid leukemia missed its primary survival goal, showing similar outcomes to midostaurin. While the company anticipates minimal financial impact for the fiscal year ending March 31, 2026, this setback raises concerns about its oncology growth ambitions. Despite an upgrade in full-year guidance, the trial disappointment may affect investor confidence in Astellas' future pipeline, which relies heavily on established brands. Analysts are reassessing revenue and earnings expectations in light of this development, suggesting a potential 12% downside to the stock's current price.

How Investors Are Reacting To Astellas Pharma (TSE:4503) XOSPATA Frontline AML Trial Missing Survival Goal

Astellas Pharma Inc.(4503.JP)

Astellas to Present Data on Long-Term Outcomes and Clinical Use of Its Portfolio Across Disease Stages at ASCO 2026 | PFE Stock News

SMC backs first-line metastatic bladder cancer combination after trial results

Astellas Pharma Inc. (TSE:4503) Just Reported Yearly Earnings: Have Analysts Changed Their Mind On The Stock?

Astellas Pharma (TSE:4503) Margin Surge To 13.6% Tests Bearish Earnings Narratives

U.S. FDA Grants Priority Review to sBLA for PADCEV™ + Keytruda® as Perioperative Treatment for Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibility | PFE Stock News